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Abnormal production of inflammatory mediators is
believed to play an important role in the pathogenesis
of psoriasis. Emerging data, both in mice and in
humans, put the spotlight on a new subset of T helper
(Th) cells, in part characterized by their production of
IL-17 and accordingly named Th17 cells. Here, we
review the development, characterization, and func-
tion of human Th17 cells as well as the crucial role of
IL-23 in the context of Th17-cell-dependent chronic
inflammation in psoriasis. We further discuss recent
clinical trials targeting the IL-23/Th17 axis in psoriasis.
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INTRODUCTION
Psoriasis is a chronic inflammatory skin disease, evolving
over time during a complex interplay between environmental
and genetic factors. Although, in the past, psoriasis has been
considered a primary keratinocyte (KC) disorder, the success-
ful treatment of psoriasis patients with cyclosporin A
suggested a potential role of the immune system in the
pathogenesis of the disease (Mueller and Herrmann, 1979).
The identification of activated CD4þ and CD8þ lympho-
cytes in psoriatic plaques and blood of psoriatic patients (Bos
et al., 1989; De Panfilis et al., 1989; Ferenczi et al., 2000),
the detection of clonally expanded T cells (Vollmer et al.,
2001), and studies of human skin xenografts in mice (Wrone-
Smith and Nickoloff, 1996; Nickoloff and Wrone-Smith,
1999; Boyman et al., 2004) supported the growing evidence
that activated T cells are the primary modulators in the
pathogenesis of psoriasis. Clinical studies on the therapeutic
efficacy of T-cell-targeted drugs further substantiated the role
of T cells in psoriasis (Abrams et al., 2000; Goedkoop et al.,
2004). Characterization of cells and cytokines involved in the
initiation and maintenance of psoriasis showed elevated
levels of IFN-g, tumor necrosis factor (TNF) -a, and IL -12, but
not IL-4, IL-5, or IL-10, at both mRNA and protein levels
(Nestle et al., 1994; Schlaak et al., 1994; Austin et al., 1999).
These observations led to the new definition of psoriasis as a
T helper (Th) 1-type disease (Lew et al., 2004).
Recently, a new population of IL-17-producing Th cells,
accordingly named Th17, has been described and its
involvement in model systems of autoimmunity shown
(Weaver et al., 2007). Furthermore, the development and
maintenance of Th17 cells have been linked to IL-23, a key
initiating cytokine in the development of autoimmunity
(Bettelli et al., 2007; Kastelein et al., 2007).
The findings of elevated levels of IL-23 and Th17-related
cytokines in cutaneous lesions and in the serum of psoriatic
patients, the association of IL23R gene variants with psoriasis,
and the evidence of a functional role of Th17 cells in
autoimmunity, provide the basis for a rising interest in the IL-
23/Th17 axis in psoriasis (Blauvelt, 2008). In this review, we
will discuss the biology and function of the IL-23/Th17
pathway, its potential dysregulation in psoriasis, and the
exciting perspective of novel therapeutics targeting the IL-23/
Th17 axis.
BIOLOGY OF IL-23 AND Th17 CELLS
IL-23 and the IL-23 receptor
IL-23 was discovered in 2000 by Oppmann and co-workers
while searching sequence databases for members of the IL-6
cytokine family (Oppmann et al., 2000). They identified a
new protein designed as IL-23p19, which had no biological
activity but, when combined with the IL-12p40 subunit of IL-
12, formed a novel heterodimeric cytokine that they named
IL-23.
IL-23 was found to be expressed by activated mouse and
human monocytes, macrophages, dendritic cells (DCs),
T cells, B cells, and endothelial cells (Oppmann et al.,
2000; Pirhonen et al., 2002). IL-23 binds to and signals
through its heterodimeric receptor complex composed of
IL-12Rb1 and IL-23R subunits (Parham et al., 2002) (Figure 1).
Whereas IL-12Rb1 is also part of the IL-12 receptor,
IL-23R is unique to the IL-23 receptor complex. IL-23R
expression on memory T cells, natural killer T cells,
monocytes, and DCs correlates with cellular responsiveness
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to IL-23 (Belladonna et al., 2002; Parham et al., 2002;
Rachitskaya et al., 2008).
Both the IL-12Rb1 and IL-23R chain lack intrinsic
signaling activity and are associated with intracellular
proteins to induce downstream signaling. IL-12Rb1 binds to
the Jak family member, Tyk2, whereas IL-23R associates with
Jak2 (Zou et al., 1997; Parham et al., 2002). IL-23 stimulation
results in ligand-induced autophosphorylation and transpho-
sphorylation of receptor-associated Jaks. Jaks in turn phos-
phorylate tyrosine residues located in the intracellular
domain of the receptor subunits. These phosphorylated
tyrosine residues serve as docking sites for the signal
transducer and activator of transcription (STAT) molecules,
which in turn also get phosphorylated. Notably, IL-23
activates a similar spectrum of STATs as IL-12: STAT1,
STAT3, STAT4, and STAT5 (Parham et al., 2002); however,
STAT3 is the main player in the IL-23 signaling pathway,
whereas STAT4 is the main player in the IL-12 pathway.
Once activated, STAT3 homodimers translocate into the
nucleus, where they bind to the DNA in the promoter region
of the target genes.
Since its discovery, IL-23 has been linked to the
pathogenesis of autoimmune inflammation. Early studies
showed that expression of IL-23p19 in multiple tissues of
transgenic mice induced systemic inflammation, runting,
infertility, and premature death (Wiekowski et al., 2001).
Interestingly, mice lacking IL-23p19 and IL-12p40 subunits,
but not those lacking the IL-12p35-specific subunit, are
resistant to animal models of autoimmunity, including
experimental autoimmune encephalomyelitis (EAE) and
collagen-induced arthritis (CIA) (Cua et al., 2003; Murphy
et al., 2003). Furthermore, the development of spontaneous
colitis in IL-10-deficient mice is completely prevented by
crossing them with IL-23p19-deficient mice (Yen et al.,
2006). These data, together with the observation that IFN-g-
producing cells are present in EAE-resistant, IL-23-deficient
mice (Langrish et al., 2005), showed that IL-23-driven
immune responses are IFN-g pathway independent and that
IL-23, rather than IL-12, is critical for the development of
autoimmune disease in these model systems. The expression
of IL-23p19 in clinical samples of Crohn’s disease (CD)
(Schmidt et al., 2005), rheumatoid arthritis (RA) (Sato et al.,
2006), and multiple sclerosis (MS) patients (Vaknin-Dem-
binsky et al., 2006; Li et al., 2007, 2008) supports a possible
role of IL-23 in common human autoimmune diseases.
Robust evidence for a role of the IL-23 pathway in
autoimmune diseases comes from recent genetic studies.
Taking advantage of recently introduced high-throughput
genotyping technologies, a number of genome-wide associa-
tion studies have been carried out to identify novel
susceptibility genes for common complex genetic diseases.
We and others have conducted such studies in psoriasis and
have identified a non-synonymous nucleotide substitution in
exon 9 of the IL23R gene, which results in an arginine to
glutamine exchange (Arg381Gln) in the cytoplasmic domain
of the receptor, showing a protective role of the variant
against psoriasis (Capon et al., 2007; Cargill et al., 2007; Nair
et al., 2008). The same effect has also been clearly
documented in CD, ulcerative colitis, (Duerr et al., 2006),
ankylosing spondylitis (Rueda et al., 2008), graft-versus-host
disease (Elmaagacli et al., 2008), and, with less significant
results, also in celiac disease and MS (Nunez et al., 2008).
Additional variants in the IL23R gene have been associated
with psoriasis (Cargill et al., 2007; Nair et al., 2008), RA
(Farago et al., 2008), Graves’ disease (Huber et al., 2008),
and MS (Illes et al., 2008), thus suggesting that variants in the
IL23R gene, may be common determinants of autoimmunity.
In addition, we and others have also shown that the IL12B
gene, coding for the IL-12p40 subunit of IL-12 and IL-23, is
associated with psoriasis (Capon et al., 2007; Cargill et al.,
2007).
Th17 cells and cytokines
Initial studies showed that IL-23 is involved in the prolifera-
tion of human and murine memory T cells (Oppmann et al.,
2000); in contrast, naı¨ve T cells do not respond to IL-23 as
they express little or no IL-23R subunit (Parham et al., 2002).
Subsequent studies showed that IL-23 promotes the expan-
sion of the novel Th17 population characterized by the
production of IL-17A and other related proinflammatory
cytokines (Aggarwal et al., 2003; Harrington et al., 2005;
Langrish et al., 2005; Park et al., 2005). CD4þ Th cells are
essential regulators of adaptive immune responses and
inflammatory diseases. After activation by professional
antigen-presenting cells, antigen-specific CD4þ T cells
differentiate into effector cells according to the cytokine
milieu, and specialize in terms of their secreted cytokines.
Th1 cells produce IFN-g as well as lymphotoxin, and are
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Figure 1. IL-23 signaling pathway. IL-23 is a heterodimeric cytokine
composed of p40 and p19 subunits. It binds to its IL-23 receptor complex
composed of IL-12Rb1 and IL-23R subunits, which are associated with the Jak
family members, Tyk2 and Jak2, respectively. IL-23 binding to its receptor
complex results in Jak2-mediated phosphorylation of tyrosine residues located
in the intracellular domain of the IL-23R subunit. Phosphorylated tyrosine
residues serve as a docking site for STAT3 molecules, which in turn get
phosphorylated. Phospho-STAT3 proteins homodimerize and translocate into
the nucleus inducing transcription of cytokines, such as IL-17A, IL-17F, IL-22
and IFN-g. Amino acid substitutions, arginine to glutamine (R381Q) and
leucine to proline (L310P), in the IL-23R subunit, conferring protection against
psoriasis, are shown.
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involved in cell-mediated immunity against intracellular
bacteria and viruses. Their development from naı¨ve T cells
depends on the presence of IL-12 and on the activation of the
master regulator transcription factor, T-bet. Th2 cells produce
IL-4, IL-5, IL-13, and IL-25 (IL-17E), and are implicated in
humoral immunity against parasites and helminthes. IL-4 and
the transcription factor GATA-3 are the key regulators of Th2
differentiation. Interestingly, each subset promotes its own
development, whereas it inhibits that of other subsets through
cytokine secretion. Immune activation that results from
dysregulated Th1 responses to self or commensal antigens
can promote autoimmune-type tissue destruction, whereas
dysregulated Th2 responses can cause allergy and asthma.
Th17 cells represent the first new lineage of effector
CD4þ T cells to be described since the original report of Th1
and Th2 subtypes by Mosmann et al. (1986) (Figure 2). IL-17A
was originally described as a product of activated memory
CD4þ T cells (Fossiez et al., 1996), but Infante-Duarte et al.
(2000) provided a first indication in 2000 that IL-17A-
producing cells cannot be categorized according to the
classical Th1/Th2 paradigm. In fact they showed that CD4þ
T cells, primed with a synthetic peptide in the presence of the
spirochete Borrelia burgdorferi, express IL-17A at signifi-
cantly higher levels than do CD4þ T cells primed in the
presence of IL-12, whereas Th2 cytokines, IL-4 and IL-10,
were inhibited under the same conditions (Infante-Duarte
et al., 2000). The concept that the IL-17-producing T cell may
be of a distinct T-cell lineage was further strengthened
by the discovery of the IL-23 function (Aggarwal et al., 2003)
and by gene-targeted mice studies. In IL-23-deficient mice,
CIA and EAE resistance correlates well with the absence
of IL-17-producing T cells, despite normal induction of IFN-g-
producing Th1 cells, thus suggesting that the former are
essential for the establishment of autoimmunity (Murphy
et al., 2003; Langrish et al., 2005). Finally, the gene
expression analysis of IL-17-producing cells identified a
unique expression pattern of proinflammatory mediators,
including IL-17A, IL-17F, IL-6, CCL20, and GM-CSF (Langrish
et al., 2005). Definitive arguments pointing toward IL-17-
producing cells as a distinct T-cell lineage arose simulta-
neously from two laboratories, showing that the development
of murine Th17 cells from naı¨ve T cells is potently inhibited
by IFN-g and IL-4 (Harrington et al., 2005; Park et al., 2005).
During recent years, cytokines and signaling pathways
involved in Th17 differentiation have been widely investi-
gated in both mice and humans. Expanding the initial in vivo
observations (Aggarwal et al., 2003; Cua et al., 2003;
Langrish et al., 2005), it has been shown later that, in mice,
IL-23 alone is not sufficient to drive in vitro Th17 differentia-
tion from naı¨ve T cells as they do not express IL-23R; rather, it
acts on the already committed Th17 population. In fact,
transforming growth factor (TGF)-b1, together with IL-6,
IL-21, and subsequently IL-23, promotes differentiation of
Th17 cells from naı¨ve CD4þ T cells (Bettelli et al., 2006;
Mangan et al., 2006; Veldhoen et al., 2006; Korn et al.,
2007). This finding was initially surprising as TGF-b1 is
known to induce the development of regulatory T cells with a
potent suppressor function (Chen et al., 2003). Consistent
with their definition as a bona fide distinct T-cell lineage,
the development of Th17 cells does not involve any of the
transcription factors implicated in Th1/Th2 differentiation.
On the contrary, both in vitro and in vivo differentiation
of Th17 cells required the TGF-b1-induced upregulation
of the unique lineage-specific transcription factor, ROR
(retinoid-related orphan receptor)gt, an orphan nuclear
receptor (Ivanov et al., 2006; Zhou et al., 2007). Furthermore,
activation of STAT3 (Mathur et al., 2007; Yang et al.,
2007), as well as involvement of the orphan nuclear
receptor RORa (Yang et al., 2008b) and of the aryl
hydrocarbon receptor (Quintana et al., 2008; Veldhoen
et al., 2008) have been suggested to be important in Th17
development.
A paucity of data regarding Th17 differentiation in humans
has been recently rectified by several publications addressing
key issues pertinent to possible differences between mouse
and human Th17 biology (Chen and O’Shea, 2008).
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Figure 2. Model for T helper (Th) or T regulatory (Treg) differentiation from
naı¨ve CD4þ T cells. Th1 cells differentiate in the presence of IL-12, and
require activation of the master regulator transcription factor, T-bet, through
STAT1. Fully committed Th1 cells express chemokine receptors, CXCR6,
CXCR3, and CCR5, and produce IFN-g and lymphotoxin through STAT4.
They are involved in cell-mediated immunity against intracellular bacteria
and viruses. Th2 cells depend on the presence of IL-4, STAT6, and GATA-3,
and release IL-4, IL-5, IL-13, and IL-25. Th2 cells express chemokine
receptors, CCR3, CCR4, and CCR8, and are important in humoral immunity
against parasites and helminthes. Th17 cells require a combination of TGF-b1
and proinflammatory cytokines (IL-1b, IL-6, and/or IL-21) to differentiate from
naı¨ve CD4þ , and RORC-(variant) 2 acts as the key transcriptional regulator.
Upregulation of the IL-23 receptor makes these cells responsive to IL-23.
Human Th17 cells produce, for example, IL-17A, IL-17F, IL-22, and IL-26,
and are important in host protection against extracellular pathogens and in
autoimmunity. Their surface markers include chemokine receptors, CCR4,
CCR6, and CD161 (not shown). In addition to effector T cells, naı¨ve CD4þ T
cells can also differentiate into induced Treg (iTreg) in the presence of IL-2
and TGF-b1 or IL-10. iTreg produces immunosuppressive cytokines, TGF-b1,
IL-10, and IL-35, and express surface markers, GITR, CD25, and CLTA-4.
Similar to thymus-derived naturally occurring Treg (nTreg, not shown), iTreg
also expresses the master regulator transcription factor, Foxp3.
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Early studies had shown that in vitro polarization of human
Th17 cells from naı¨ve CD4þ cells occurs in the presence of
toll-like receptor-activated monocytes (Evans et al., 2007)
and also that proinflammatory cytokines, such as IL-1b and
IL-6, alone or in combination with IL-23, were able to drive
Th17 differentiation (Chen et al., 2007; Wilson et al., 2007;
Acosta-Rodriguez et al., 2007a). In particular, IL-1b was
sufficient to induce the expression of RORC variant 2,
the human ortholog of mouse RORgt, and the production of
both IL-17A and IFN-g (Acosta-Rodriguez et al., 2007a),
whereas a combination of IL-6 and IL-1b promoted the
differentiation of T cells producing IL-17A, but not IFN-g
(Acosta-Rodriguez et al., 2007a). Surface phenotype analysis
of these cells showed that IL-17A-producing cells express the
chemokine receptors, CCR6 and CCR4, whereas IFN-g/IL-17-
producing cells express CCR6 and CXCR3 (Acosta-Rodriguez
et al., 2007b). Recently, CD161 has been found to be
expressed in IL-17A-producing cells and has been suggested
as a novel surface marker for human Th17 cells (Cosmi et al.,
2008).
However, the most challenging aspect of human Th17
biology is the role of TGFb-1. Although dismissed for a while,
an absolute need for TGFb-1 in human Th17 differentiation is
now being recognized (O’Garra et al., 2008). Initial studies
showed that TGFb-1 does not promote Th17 differentiation
but rather inhibits IL-17A production in a dose-dependent
manner (Chen et al., 2007; Wilson et al., 2007; Acosta-
Rodriguez et al., 2007a). However, recent reports have
shown that in humans also, low concentrations of TGFb-1 are
necessary to differentiate human naı¨ve CD4þ T cells into
Th17 cells, either in combination with IL-21 (Yang et al.,
2008a), with IL-1b and IL-23 (Manel et al., 2008) or with
IL-1b, IL-23, and IL-6 (Volpe et al., 2008). Although these
studies differ slightly in their conclusions about the relative
role of proinflammatory mediators, they have collectively
shown that, similar to that in mice (Zhou et al., 2008), TGF-
b1 concentration and the concomitant presence of at least
one proinflammatory cytokine are key factors in human Th17
differentiation. In fact, low concentrations of TGF-b1
synergizes with proinflammatory cytokines such as IL-1b,
IL-6, IL-21, and IL-23 (Manel et al., 2008; Yang et al., 2008a)
to promote IL-23R expression, thus favoring the differentia-
tion of naı¨ve cells into the Th17 effector lineage, whereas,
high levels of TGF-b1 and the absence of inflammatory
cytokines would rather inhibit Th17 differentiation, shifting
the balance toward regulatory T cell development (Manel
et al., 2008). The presence of a discrete amount of TGF-b1 in
the human and bovine serum used in earlier studies probably
accounts for the inability to observe TGF-b-induced Th17
differentiation. Finally, using a different approach on the
basis of particular genetic traits affecting putative Th17-
relevant signals, de Beaucoudrey et al. (2008) have recently
confirmed that, among other cytokines, IL-23 is indeed
required for an optimal development of human Th17 cells.
In parallel to factors required for Th17 commitment,
natural inhibitors of Th17 development have also been
identified. As mentioned, both Th1 (IFN-g) and Th2 (IL-4)
cytokines inhibit Th17 differentiation (Harrington et al.,
2005; Park et al., 2005). More recently, IL-25, a member of
the IL-17 family earlier known as IL-17E and involved in Th2
response (Angkasekwinai et al., 2007), has been found to
negatively regulate Th17 cells by inhibiting the expression of
IL-1b and IL-23 by DC (Kleinschek et al., 2007). Likewise,
IL-27, belonging to the IL-6 family (Pflanz et al., 2002), also
acts as a Th17 inhibitor, consistent with its capacity to drive a
Th1 cell response (Batten et al., 2006; Stumhofer et al., 2006).
In addition to IL-17A, Th17 cells have been collectively
shown to also produce IL-17F, IL-22, and IL-26, as well as
IL-6, IL-21, TNF-a, and IFN-g (Chen et al., 2007; Wilson
et al., 2007; Acosta-Rodriguez et al., 2007a; Manel et al.,
2008; Volpe et al., 2008). To date, IL-17A, IL-17F, and IL-26
are considered to be specific Th17 cytokines (Manel et al.,
2008), whereas the others, including IL-22, can be produced
by Th1 cells also (Volpe et al., 2008). In this review, we will
focus our attention on those cytokines produced by Th17
cells that have been shown to be of potential relevance to
cutaneous inflammation.
Human IL-17A is the founding member of the IL-17
cytokine family, which includes six members, IL-17A to
F. Very little is known about IL-17B, IL-17C, and IL-17D,
which are produced by non-T-cell sources, whereas IL-17E
has been renamed IL-25 and IL-17F shares many features with
IL-17A (Weaver et al., 2007). Although Th17 cells are the
major source of IL-17A, other IL-17A-producing cells have
also been reported, including CD8þ cells (Shin et al., 1999),
gd-TCR cells (Roark et al., 2008), and natural killer T cells
(Rachitskaya et al., 2008). IL-17F shares 50% sequence
homology with IL-17A and both cytokines can exist either as
IL-17A and IL-17F homodimers or as IL-17A-IL-17F hetero-
dimers (Liang et al., 2007). They all induce the expression of
diverse proinflammatory cytokines (for example, IL-1b and
IL-6), colony-stimulating factors (for example, GM-CSF and
granulocyte colony-stimulating factors), and chemokines (for
example, CXCL8, CXCL1, and CXCL10) from a variety of
cells, including monocyte/macrophages, and epithelial cells.
Accordingly, IL-17A and IL-17F have potent activity to
mobilize, recruit, and activate neutrophils, thus linking
adaptive and innate immunity (Weaver et al., 2007).
IL-22 is a member of the IL-10 cytokines family, and is
mainly produced by T and natural killer cells (Wolk et al.,
2002). Neither resting nor activated immune cells respond to
IL-22. In contrast, tissue cells at outer body barriers, that is, of
the skin, kidney, and the digestive and respiratory systems are
targets of this cytokine. IL-22 functions by promoting
antimicrobial defense mechanisms, protecting against tissue
damage, and re-organizing non-immune tissues, such as
epithelia, thus regulating terminal differentiation of KCs
(Wolk and Sabat, 2006).
Functional analysis of Th17 cytokines has revealed an
important and unique role for these cytokines in host
protection against infections with extracellular pathogens.
IL-17R-deficient mice are highly susceptible to infection by
the Gram-negative bacterium, Klebsiella pneumoniae, and
the fungus, Candida albicans (Ye et al., 2001; Huang et al.,
2004). In addition, the preferential production of IL-17 by T
cells during infection by Bacteroides fragilis (Chung et al.,
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2003), Borrelia burgdorferi, Mycobacterium tuberculosis
(Infante-Duarte et al., 2000), and the fungal species
(LeibundGut-Landmann et al., 2007), suggests that Th17
responses are triggered by specific pathogens and are
required for their clearance. These data are supported by
recent findings showing that null mutations in IL12B and
IL12RB1 genes lead to impaired IL-17-producing T-cell
development in patients with autosomal-recessive suscept-
ibility to mycobacterial diseases (de Beaucoudrey et al.,
2008). A number of autoimmune disorders have been
associated with overproduction of Th17 cytokines, and
interference with their production or action attenuate
autoimmune diseases. IL-17-deficient mice are resistant to
adjuvant-induced arthritis (Nakae et al., 2003) and develop
EAE with delayed onset and reduced severity (Komiyama
et al., 2006). Similarly, IL-17R antagonists (Bush et al., 2002)
and IL-17A-blocking antibodies (Abs) (Hofstetter et al., 2005;
Langrish et al., 2005) prevent the development of auto-
immune diseases.
Under homeostatic conditions, IL-17A is present in
extremely low or undetectable concentrations in human sera
but has been reported to be overproduced at the both serum
and tissue level in inflammatory bowel diseases, MS, and RA;
(Kotake et al., 1999; Matusevicius et al., 1999; Lock et al.,
2002; Fujino et al., 2003). Similarly, IL-22-expressing T-cells
are present in inflamed regions of the gut in patients with
inflammatory bowel diseases but not in the normal colonic
mucosa (Andoh et al., 2005). IL-22 expression was also
described in both synovial tissues and in mononuclear cells
of the synovial fluid from RA patients (Ikeuchi et al., 2005).
ROLE OF IL-23 AND TH17 CELLS IN PSORIASIS
IL-23 and the IL-23 receptor in psoriasis
The role of IL-23 and IL-23R in cutaneous inflammation has
been investigated both in mice and in humans. Intradermal
injection of IL-23 in mice led to erythema, induration, and
prominent dermal papillary blood vessels with histopatholo-
gical features resembling psoriasis (Chan et al., 2006). The
morphological features of the IL-23-induced skin lesions were
more severe than the ones induced by IL-12 (Zheng et al.,
2007). Furthermore, IL-23 was shown to mediate epidermal
hyperplasia, acanthosis, hyperparakeratosis, and orthohyper-
keratosis through TNF-a and IL-20R2 (Chan et al., 2006). In a
transgenic mouse model of skin inflammation overexpressing
the common IL-12/IL-23 subunit, IL-12p40, under the
influence of the keratin 14 promoter, it was shown that IL-
12p40 and IL-23p19, but not IL-12p35, were constitutively
produced by basal KCs (Kopp et al., 2003). These data were
complemented in humans by Lee et al. (2004) showing
overexpression of IL-23p19 and IL-12p40, in the absence of
IL-12p35, at the mRNA level in psoriatic skin lesions, when
compared with that in uninvolved skin. IL-23p19 was mostly
localized in the papillary dermis, and it was strongly
expressed in monocytes, monocyte-derived DCs, and in
mature DCs. Collectively, these data indicate that production
of IL-23 occurs at inflammatory skin sites and is mediated by
tissue-resident and/or recruited immune cells, such as DCs,
and possibly KCs (Piskin et al., 2006).
Little is known about the immediate downstream effects of
IL-23 in psoriasis. IL-23 signals through the IL-23 receptor
complex expressed on DCs, lymphocytes, natural killer T
cells, and KCs. It has been recently shown that IL-23, in
synergy with IL-1b, is able to enhance production of human-
b-defensin-2, an antimicrobial peptide increased in psoriasis,
in normal human KCs (Kanda and Watanabe, 2008). Further
evidence supporting a pathogenic role of IL-23 in psoriasis
comes from the clinical data. Zaba et al. (2007) have shown
that anti-TNF-a agents are able to modulate IL-23p19 and IL-
12p40 mRNA levels, and the inflammatory infiltrate in the
psoriatic skin. Furthermore, modulation of IL-23 by cyclos-
porin A, UV therapy, and by biological agents has been
correlated to the clinical benefit in psoriatic patients (Piskin
et al., 2004; Gottlieb et al., 2005; Lowes et al., 2008; Haider
et al., 2008b).
Finally, detailed genetic studies of the IL23R gene in
psoriasis have recently shown that at least two non-
synonymous single nucleotide polymorphisms, Arg381Gln
and proline to leucine (Pro310Leu), independently contribute
to a psoriasis phenotype (Capon et al., 2007; Cargill et al.,
2007; Nair et al., 2008). These convincing genetic data, in
combination with data showing an association between
IL-12B and psoriasis, support the importance of the IL-23 (and
possibly IL-12) pathway in psoriasis.
Th17 cells and cytokines in psoriasis
Consistent with the described role of Th17 cells in a variety of
chronic inflammatory autoimmune-type diseases, there is a
growing body of evidence supporting a major role of Th17
cells and Th17-related cytokines in psoriasis. The first
observation that IL-17 could be a relevant cytokine in
psoriasis was found in the late 1990s. Teunissen et al.
(1998) showed detectable levels of IL-17 mRNA in lesional
psoriatic skin, but not in non-lesional skin, and showed that
CD4þ and CD8þ clones derived from lesional psoriatic
skin were able to produce IL-17 after stimulation with CD3/
CD28 Abs. IL-17 was also shown to promote the production
of IL-6, IL-8, GM-CSF, and ICAM-1 in KCs, synergizing with
IFN-g (Albanesi et al., 2000; Koga et al., 2008). IL-17-
producing cells have been isolated from the dermis of
psoriatic lesions (Lowes et al., 2008). Dermal localization
of Th17 cells has also been documented in atopic dermatitis,
with a higher percentage of IL-17-producing cells present in
acute rather than in chronic lesions (Koga et al., 2008).
Surface phenotypic analysis of IL-17-producing T cells
derived from psoriatic skin as well as from intestinal biopsies
of patients affected with CD, showed a predominantly
CD161þ phenotype (Cosmi et al., 2008). DCs isolated from
psoriatic skin are able to increase the percentage of IL-17A
production in allogenic T cells (Zaba et al., 2009).
Interestingly, in contrast to other potential Th17-type
autoimmune diseases such as RA (Chabaud et al., 1999;
Kohno et al., 2008), CD (Fujino et al., 2003), MS
(Matusevicius et al., 1999), systemic lupus erythematosus
(Wong et al., 2000), and systemic sclerosis (Kurasawa et al.,
2000), no statistically significant differences in peripheral
levels of IL-17A have been found in psoriatic patients when
www.jidonline.org 1343
A Di Cesare et al.
Immunopathogenesis of Psoriasis
compared with that in controls (Arican et al., 2005). This
suggests that the major site of production of IL-17A in
psoriasis may be the lesional skin infiltrated by Th17 cells.
This concept is strengthened by the data derived from studies
on cytokine profiles after various immunomodulatory treat-
ments in RA and psoriatic patients. In RA, the efficacy of both
cyclosporin A and anti-TNF-a therapies has been correlated
to modulation of proinflammatory cytokines, both in periph-
eral blood and in synovia (Cho et al., 2007; Kageyama et al.,
2007). In contrast, in psoriasis, the use of cyclosporin A and
anti-TNF-a agents has been reported to decrease cutaneous,
but not peripheral, levels of proinflammatory cytokines, such
as IFN-g, IL-17A, IL-23p19, and CCL20 (Zaba et al., 2007;
Lowes et al., 2008; Haider et al., 2008a, b).
A key cytokine produced by Th17 cells is IL-22. The role
of IL-22 in the pathogenesis of psoriasis has been extensively
examined because of its peculiar activities in immune innate
response and functions on epithelial cells (Wolk et al., 2006).
IL-22, as well as IL-17, TNF-a, IL-1b, IL-6, IL-12p40, and IL-
12, has been found elevated in ear tissues of a psoriasiform
mouse model, that is, transgenic K14/VEGF mice treated with
12-O-tetradecanoyl phorbol-13-acetate (Hvid et al., 2008).
IL-23 injection in rodents induces IL-22-dependent dermal
inflammation, KC hyperproliferation, and epidermal acantho-
sis (Wolk et al., 2006; Zheng et al., 2007). In a CD4 T-cell-
dependent psoriasis mouse model, an IL-22-neutralizing Ab
was able to modulate the cutaneous expression of S100A8,
S100A9, defensin b1, and cathelicidins, as well as prevent
the development of skin lesions (Ma et al., 2008).
In vitro studies have shown that IL-22 synergizes with IL-
17A and IL-17F to enhance the KC expression of antimicro-
bial peptides (Liang et al., 2006; Wilson et al., 2007). IL-22
can also drive epithelial cell release of chemokines, such as
IL-8 (Brand et al., 2006; Liang et al., 2006; Koga et al., 2008),
a key factor for neutrophil recruitment into psoriatic lesions.
Moreover, in reconstituted human epidermis, KCs express
genes involved in tissue repair and wound healing responses
on stimulation with IL-22 (Sa et al., 2007).
Finally, increased IL-22 mRNA and protein levels have
been found both in the skin and blood of psoriatic patients
(Wolk et al., 2006; Boniface et al., 2007). IL-22 mRNA levels
were higher in lesional skin than in psoriatic peripheral
monocytes (Boniface et al., 2007).
From these data, a concept emerges that IL-17A and IL-22
are key mediators of cutaneous inflammation, linking Th17
pathology with epithelial pathology, thus contributing to the
pathogenesis of psoriasis (Figure 3). The IL-23/Th17 axis
model for psoriasis integrates the well-defined type-1
inflammatory pathway model, in which Th1, Tc1 (cytotoxic
T cell type-1) lymphocytes, and DCs are the central
orchestrators of the events leading to psoriasis (Lew et al.,
2004). The molecular spectrum of the type-1 model of
psoriasis is dominated by IL-12, produced by DCs, TNF-a,
and IFN-g, released by Th1 and Tc1 lymphocytes, which act
on KCs by increasing their proliferation rates and stimulating
their ability to release proinflammatory mediators. Typically,
in the psoriatic plaque, Th1 lymphocytes are localized
in the dermis, whereas Tc1 lymphocytes are mainly found
in the epidermis expressing a1b1 integrin (VLA-1, very late
antigen-1), which binds to basement membrane collagen IV
(Conrad et al., 2007). Therefore, it can be postulated that,
in the psoriatic plaque, dermal dendritic cells produce both
IL-12 and IL-23, driving a mixed type-1/Th17 infiltrate that
interacts with KCs, fibroblasts, endothelial cells, and neu-
trophils to create a psoriatic plaque.
Targeting the IL-23/Th17 pathway in the treatment of psoriasis
Novel insights into the immunopathogenesis of psoriasis have
led to the development of new effective therapies, character-
ized by highly selective mechanisms of action, targeting key
immune cytokines and receptors.
With regard to the IL-23/Th17 axis, targeting the common
subunit, p40, of IL-12 and IL-23 has shown clinical benefits in
autoimmune-type diseases, such as CD and psoriasis. Two
anti-IL-12p40 monoclonal Abs have been developed,
namely, CNTO-1275/ustekinumab and ABT-874. An oral
IL-12/23 inhibitor has been tested in early clinical trials in CD
(Burakoff et al., 2006).
Figure 3. Th17 lymphocytes and psoriasis: cellular and molecular
interactions with skin-resident cells. In the ‘IL-23/Th17 axis’ model for
psoriasis, Th17 lymphocytes (Th17) interact with skin-resident cells,
contributing to the psoriatic phenotype. In the dermis, IL-23, secreted by
dermal dendritic cells (DDC), is able to induce Th17 lymphocyte activation
with the consequent release of proinflammatory cytokines, such as IL-17A, IL-
17F, IL-22, and IL-26. IL-17A, IL-17F, and IL-22 act on keratinocytes (KC)
leading to epidermal hyperplasia, acanthosis, and hyperparakeratosis. Dermal
CCR5þCXCR3þCXCR6þ Th1 and epidermal VLA-1þ Tc1 lymphocytes
are activated by DDCs and produce TNF-a and IFN-g, contributing to the
pathogenesis of the disease. KC hyperproliferation might also be influenced
by fibroblasts, which can release keratinocyte growth factor (KGF) through
TNF-a stimulation. In the context of this proinflammatory milieu, activated
KCs might produce IL-23, which could mediate a cross-talk with Th17
lymphocytes in synergy with IL-23 coming from DDC. Th17 cells induce KC
to produce IL-8 and antimicrobial peptides (for example, S100A8, S100A9,
and defensin b1/2) for recruitment of neutrophils, cathelicidin for activation of
plasmacytoid dendritic cells (PDC), and vascular endothelial growth factor
(VEGF) with resulting angiogenesis.
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Both CNTO-1275 and ABT-874 are human IgG1 MAbs
that bind to the p40 subunit of human IL-12 and IL-23, and
prevent its interaction with IL-12Rb1. Preclinical analyses in
cynomolgus monkeys, in the monkey asthma model and in
the marmoset model for MS, and in vitro studies have been
conducted to evaluate the safety of anti-IL-12p40 (Brok et al.,
2002; t Hart et al., 2005). It has also been shown that anti-IL-
12p40 can lead to a decrease in disease activity in the mouse
models of MS (Leonard et al., 1997) and CD (Neurath et al.,
1995). Anti-IL-12p40 successfully abolished psoriatic lesions
in mice, even when administered after transfer of the T-cell
subset that induced the psoriasis-like condition (Hong et al.,
1999; Ma et al., 2008).
In humans, results from phase I (Kauffman et al., 2004) and
phase II studies (Krueger et al., 2007; Kimball et al., 2008)
have shown that both CNTO-1275 and ABT-874 can be
appropriate treatments for moderate-to-severe psoriasis (Nes-
tle and Conrad, 2004), being able to modulate IL-8, IL-18,
IFN-g, cutaneous lymphocyte antigens (CLA), IL-12R, CD40L,
and IL-2Ra expressions and to inhibit the secretion of
cytokines induced by IL-12, and IL-23 in psoriasis as well
as in CD (Fuss et al., 2006; Toichi et al., 2006; Gottlieb et al.,
2007; Reddy et al., 2007). Indeed, clinical data from phase II
studies on anti-IL-12p40 in CD further support IL-12p40 as an
appropriate target for CD therapy (Mannon et al., 2004).
Notably, an oral treatment, STA-5326, which acts as a
selective transcription inhibitor with potent anti-IL-12 and
anti-IL-23 activity, has been reported as effective in pre-
clinical studies on rat and murine models of CD and in a
phase I/IIA trial in active moderate-to-severe CD (Burakoff
et al., 2006; Wada et al., 2007).
Currently, several phase III trials have been published or are
ongoing to evaluate the efficacy and safety of the anti-IL-12p40
MAb versus placebo or etanercept (anti-TNF-a therapy) in the
treatment of moderate-to-severe chronic plaque psoriasis.
Leonardi et al. and Papp et al. have published the results of
the PHOENIX 1 (Leonardi et al., 2008) and PHOENIX 2 (Papp
et al., 2008), phase III, randomized, placebo-controlled trials
evaluating the efficacy and safety of ustekinumab in
moderate-to-severe psoriasis.
The PHOENIX 1 trial assessed the efficacy and safety of
ustekinumab 45 and 90 mg, administered subcutaneously at
weeks 0, 4, and then every 12 weeks over 76 weeks of
treatment. Overall, a larger number of patients in the
ustekinumab arm (both 45 and 90 mg) achieved PASI
(Psoriasis Area and Severity Index)-75 at week 12 when
compared with those in placebo (PASI-75 response in 67.1,
66.4, and 3.1%, respectively). Efficacy increased over time
with the maximum effect at week 24 (PASI-75 response
observed in 76.1% of patients treated with 45 mg and in 85%
of patients in the 90 mg group) and improvement in the PASI
score remained stable up to at least week 76. The occurrence
of adverse events was similar during the whole duration of
the study; it was not statistically different from the placebo
group, and did not require treatment adjustment. The most
commonly reported adverse events were mild and considered
non-serious, and mostly consisted of upper respiratory tract
infections, nasopharyngitis, headache, and arthralgia.
The aim of the PHOENIX 2 trial was to assess whether
dosing intensification would increase the response to treat-
ment in partial responder patients (between PASI-50 and
PASI-75). The results up to week 28 were comparable with
the ones reported in PHOENIX 1. At week 28, patients who
responded to ustekinumab continued to receive the study
agent every 12 weeks and maintained a good response up to
week 52. Partial responders at week 28 (22.7 and 15.8% of
patients in the 45 and 90 mg group, respectively) were
randomly assigned to continue treatment every 12 weeks or,
through an intensified regimen, every 8 weeks. Dosing
intensification did result in increased clinical efficacy only
in patients receiving 90 mg, and not 45 mg, of ustekinumab
every 8 weeks (PASI-75 in 68.8% of patients receiving 90 mg
every 8 weeks versus 33.3% of patients receiving 90 mg every
12 weeks). The incidence and the kind of adverse events that
occurred during the PHOENIX 2 study did not differ from
those reported in the PHOENIX 1 trial.
Overall, the results of the clinical studies on the efficacy of
anti-IL-12p40 Abs observed so far are promising, suggesting
that ustekinumab and possibly ABT-874 could provide a new
and effective treatment for moderate-to-severe psoriasis, thus
stressing the important role of IL-12/IL-23 in the pathogenesis
of the disease. Moreover, anti-IL-12p40 Abs have so far
shown a good safety profile during treatment periods of up to
76 weeks. Nevertheless, long-term safety issues are to be
considered given the relevant part played by IL-12p40 in host
defense (Trinchieri, 1998), potentially leading to increased
susceptibility to infections in patients treated with anti-IL-
12p40. In humans, mutations in the IL-12p40 subunit or in its
receptor have been associated with susceptibility to tubercu-
losis and salmonella infections, but not to viral or fungal
infections (Altare et al., 1998; de Jong et al., 1998; Oxenius
et al., 1999).
Taken together, targeting both IL-12 and IL-23 is a highly
effective therapeutic approach in chronic plaque-type psor-
iasis. Future studies will show if targeting IL-23 on its own
will be effective. Longer follow-up periods with the establish-
ment of treatment registries are necessary to confirm the
safety of anti-IL-12p40 Abs in the treatment of moderate-to-
severe chronic plaque psoriasis.
CONCLUSIONS
A significant amount of both clinical and experimental data
have established Th17 cells as key players in chronic
inflammatory conditions, such as psoriasis, providing an
exciting advance in our understanding of psoriasis immuno-
pathogenesis and novel therapeutic targets.
This puts the spotlight on IL-23, which is secreted by skin
DCs, and induces production of proinflammatory mediators
by Th17 cells such as IL-17A, IL-17F, and IL-22. These
mediators will act on KCs leading to their activation and
hyperproliferation. In the cross-talk between KC and Th17
cells, activated KCs produce key proinflammatory cytokines,
chemokines, and antimicrobial peptides, which are able to
recruit and activate immune cells in the inflamed skin. These
events result in amplification of the immune response,
leading to the clinical features of the disease.
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Integration of the IL-23/Th17 axis into a revised concept of
psoriasis pathogenesis has been already translated into novel
therapeutic strategies, which are proving to be effective and
safe in the treatment of chronic plaque psoriasis. Future
investigations will further clarify the role of key components
of the IL-23/Th17 axis, and their interplay with other relevant
cellular and molecular pathways of the innate and adaptive
immune system in psoriasis.
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